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Abstract Lysyl oxidase (LO) is a copper amine oxidase of the 
e~,tracellular matrix which initiates covalent cross-linking in 
collagens and elastin. Human LO was expressed in Escherichia 
coli. At 37°C, large amounts of protein were obtained, but in the 
form of insoluble aggregates. Lowering the growth temperature, 
and reducing the amount of inducer, resulted in the production of 
soluble LO, which was active on a [3H]lysine-laheled elastin 
substrate. LO was also targeted to the periplasm as a fusion 
protein with the pelb signal peptide. The periplasmic enzyme was 
soluble, active and inhibited by [$-aminopropionitrile. Production 
of the carbonyl co-factor is therefore not a limitation in the 
expression of active LO in bacteria. 
Aey words: Lysyl oxidase; Copper amine oxidase; Protein 
e~pression; Bacteria 
I Introduction 
The formation of lysine- (or hydroxylysine-) derived cova- 
knt cross-links in collagens and elastin is essential for the 
s ructural integrity and function of connective tissues [1,2]. 
q he enzyme that initiates cross-linking, lysyl oxidase (EC 
1 4,3.13), is a copper-dependent amine oxidase of the extra- 
czllular matrix that oxidatively de-aminates the ~-amino 
roups of specific lysine (and hydroxylysine) residues, leading 
t ~ the spontaneous formation of a number of bi-functional, 
t i-functional and tetra-functional crosslinks [3]. As the ter- 
vfinal enzymatic step in the biosynthetic pathway of collagens 
~nd elastin, lysyl oxidase (LO) is a potential target in the 
9ntrol of fibrotic disease. LO has also been implicated in 
11mor suppression, as the product of the ras recision gene 
after oncogenic transformation of mouse fibroblasts [4]. In 
~:ddition, the enzyme has been shown to be a potent chemo- 
1 tctic agent for unstimulated human peripheral blood mono- 
t ytes [5]. 
Lysyl oxidase (29 kDa) is secreted in precursor form (50 
Da), and conversion to the mature form of the enzyme oc- 
turs by proteolytic removal of an N-terminal propeptide [6]. 
We have recently identified [7] the propeptide cleavage site in 
t,orcine pro-LO as gly-asp, which corresponds to residues 
68-169 in the human LO precursor. This sequence also cor- 
~,~sponds to the C-terminal processing site of fibrillar collagen 
l recursors by procollagen C-proteinase, the enzyme that has 
~ecently been shown to be the same as bone morphogenetic 
t,rotein-I (BMP-1) [8,9]. The sequence data suggest that BMP- 
may be required for processing of both pro-LO and the 
precursor forms of its collagen substrates [7], a suggestion 
1hat has recently received experimental support [10]. 
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The nature of the carbonyl co-factor in lysyl oxidase has 
been the subject of much controversy [11]. Trihydroxyphenyl- 
alanine (topa) quinone has been shown to be the co-factor in 
a number of copper-dependent amine oxidases from E. co~i, 
yeast, plants and mammals [11 13], where the presence of the 
Asn-Tyr-Asp consensus equence appears to be sufficient for 
the spontaneous conversion of polypeptide bound tyrosine to 
topaquinone, in the presence of copper and oxygen [12]. This 
consensus sequence is not present in LO. Very recently, it has 
been demonstrated [14] that LO contains a novel quinone co- 
factor, designated lysine tyrosylquinone (LTQ), which is de- 
rived from the cross-linking of the e-amino group of a peptid- 
yl lysine with the modified side chain of a tyrosine residue. 
Structure-function studies on LO using physical techniques 
(e,g. X-ray crystallography) have been hampered by the diffi- 
culty in obtaining adequate amounts of enzyme. The small 
amounts of enzyme that can be purified from tissues require 
the presence of denaturing agents (4-6 M urea) for efficient 
extraction. Enzyme activity is recovered after dilution/dialysis 
of tissue-derived enzyme into physiological buffers, but this 
also results in the formation of high molecular mass aggre- 
gates [15]. It is not known if this aggregation is physiologically 
significant or merely the result of partial, irreversible denat- 
uration by urea. Modest amounts of enzymatically active, 
recombinant rat LO have recently been expressed in mamma- 
lian cells [16], but not in the amounts that would be required 
for crystallisation trials. Here we report the efficient expres- 
sion of milligram amounts of active, human LO in E. coli, 
which paves the way for 3-dimensional structure-function 
studies of the enzyme and its interactions with collagen and 
elastin substrates. In addition, these results show that forma- 
tion of the LTQ co-factor is not a limitation in the bacterial 
expression of this enzyme. 
2. Materials and methods 
2.1. Bacterial strains and plasmid construction 
The E. coli strain JM109 (Promega) was used for transformation 
and propagation ofplasmids, while the E. coli strain BL21(F- ompT 
r-B m-B; DE3; Novagen) was used for recombinant expression of 
LO. Both pET3d and pET20b expression vectors were from Novagen. 
The cDNA encoding the mature form of LO was amplified by the 
polymerase chain reaction, using Vent DNA polymerase (New Eng- 
land Biolabs), from a human placenta cDNA library (Clontech). PCR 
primers (5'-CCATGGACGACCCTTACAACCCCTAC-3' and 5'-G- 
GATCCTCAATACGGTGAAATTGTGCAGCCT-3') were designed 
to introduce unique NcoI and BamHI restriction sites at the 5' and 3' 
ends of the gene, respectively. The amplified fragment (761 bp) was 
subcloned into the Sinai site of pGEM 3Z (Promega) to create the 
plasmid pGEM-LOm. Plasmid constructions were performed using 
established techniques [17] and cloning steps were verified by DNA 
sequencing [18]. 
For cytoplasmic expression of LO, the sequence encoding the ma- 
ture form of the enzyme was isolated as a 761 bp NeoI-BamHI frag- 
ment from pGEM-LOm and ligated into the Ncol BamHl sites of the 
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pET3d expression vector [19] to create the construct pET3-LOm. For 
periplasmic expression of LO, the NcoI BamHI fragment was ligated 
into the NcoI-BamHI opened pET20b expression vector, in frame 
with the sequence coding for the pelb signal peptide, to create the 
construct pET20-LO. In both expression constructs, the LO gene 
was under the control of the T7 gene 10 promoter and ribosome 
binding site (Fig. 1). 
2.2. Expression and preparation of recombinant proteins 
E. coli BL21(DE3), transformed with the vector pET3-LOm (for 
intracellular expression) or pET20-LO (for periplasmic expression), 
was grown in 100 ml of LB medium containing ampicillin (50 /.tg/ 
ml), at 37°C or 22°C, until an OD600 of 0.5~0.6 was reached. Isopro- 
pyl-~-D-thiogalactopyranoside (IPTG; 0.4 mM or 0.04 mM) was 
added and the incubation was continued for 3 h. Cells were harvested 
by centrifugation at 5000xg for 15 rain at 4°C. 
Prior to extraction, cells were resuspended in ice-cold 50 mM Tris- 
HCI, 1 mM phenylmethylsulfony! fluoride, pH 8.0 (lysis buffer). Cell 
disruption was accomplished by sonication at 60% efficiency with a 
micro-tip-type sonicator (Sanyo). Lysates were then centrifuged at 
5000xg for 10 min to remove cell debris and supernatants were 
further centrifuged at 12000Xg for 20 rain to precipitate inclusion 
bodies [20]. The inclusion bodies were homogenised in 6 ml of 50 mM 
Tris-HCl, 0.5% (v/v) Triton-X100, pH 8.0 (Triton wash) and incu- 
bated for 10 min at room temperature. The solution was then centri- 
fuged at 12000Xg for 15 min. The pellet (Triton-washed inclusion 
bodies) was solubilised in 10 ml of 20 mM Tris-HCl, 250 mM NaC1, 
0.01% (v/v) Tween 80, 8 M urea, pH 8.5, and incubated at room 
temperature for 1 h, with gentle stirring. The solution was then diluted 
by addition of 9 volumes of 20 mM Tris-HCl, 250 mM NaCI, 0.01% 
(v/v) Tween 80, pH 8.5, and further incubated at room temperature 
for 2 h. Finally the solution was dialysed extensively against phos- 
phate-buffered saline (PBS: 0.15 M NaCl, 0.1 M sodium phosphate, 
pH 7.2). Under these conditions LO precipitated selectively out of 
solution and could be recovered by centrifugation for 15 min at 
12000xg. Preparation of periplasmic proteins was achieved by os- 
motic shock [21], followed by dialysis into PBS. 
2.3. Immunological procedures and protein analysis 
Rabbits were injected subcutaneously at multiple sites with a total 
of 100 #.tg of purified protein mixed 1:1 (v/v) with complete Freund's 
adjuvant (Sigma). Three booster injections were given at 4-week inter- 
vals with the same quantity of protein in incomplete Freund's adju- 
vant. Production of antibodies was checked by immunoblotting 8 days 
after each injection. The IgG fraction was isolated using caprilic acid 
and ammonium sulfate precipitation [22]. 
Protein concentrations were measured [23] using bovine serum al- 
bumin as standard. SDS-PAGE was performed essentially as de- 
scribed [24], followed by staining with Coomassie Brilliant Blue. lm- 
munoblotting was carried out on Immobilon-P membrane (Millipore) 
by semi-dry electrotransfer (Pharmacia). Immunological detection was 
accomplished using anti-LO IgG and immunopurified anti-rabbit IgG 
alkaline phosphatase conjugates (Pierce). 
2.4. Enzyme assay and purification of porcine lysyl oxidase 
Enzyme activity was assayed by ultrafiltration [25] using an elastin 
substrate prepared as described [26] from chick aorta cultured for 24 h 
in the presence of L-[4,5-3H]lysine. For each assay, 100 /.tl of 
[3H]elastin (300000 dpm) was incubated for 16 h at 35°C with 700 
~tl of assay buffer (0.1 M Na2B4OT, 0.15 M NaCI, pH 8.0) and 100 ~1 
of enzyme or buffer control. The reaction was stopped by the addition 
of 100 lal of 50% (w/v) trichloroacetic a id, followed by centrifugation 
(5 rain at 12 000 x g) and ultrafiltration of the supernatant [25]. Assays 
were also carried out in the presence of 50 ~tg/m143-aminopropionitrile 
(BAPN), a specific inhibitor of LO, after pre-incubation with the 
enzyme for 2 h prior to the addition of [3H]elastin substrate. Results 
are expressed (Table l) per milliliter of assay mixture, after subtrac- 
tion of background activity (i.e. substrate and assay buffer alone). 
Lysyl oxidase was purified from urea extracts of piglet skin [25,27] 
using a procedure originally devised for bovine aorta [28], modified by 
the use of a Superdex 75 gel permeation column in place of Sephacryl 
S-200 in the final purification step. The purified enzyme (specific ac- 
tivity: 1730 cprn/ml/p.g protein), which appeared as a single band at 32 
kDa by SDS-PAGE and Coomassie Blue staining, was stored at 
-20°C in 6 M urea, 16 mM sodium phosphate buffer, pH 7.7. 
3. Resu l t s  
The cDNA coding for the mature form of LO was ampli- 
fied by PCR from a human placental cDNA library and 
cloned into the pGEM3Z plasmid. Sequencing of the DNA 
confirmed the data previously reported for human placental 
LO [29] with the exception of two nucleotides (TG to GT) at 
position 943-944 in the sequence ncoding the full-length LO 
precursor, which resulted in a Trp to Val replacement at res- 
idue 315 in the protein sequence. Valine is also found in the 
corresponding position in the cDNA-derived, predicted amino 
acid sequences of human skin fibroblast [30], rat aorta [31], 
chick aorta [32] and mouse [33] LO. In addition, human geno- 
mic LO has also been reported to code for valine at residue 
315 in the protein sequence [34]. 
The human LO cDNA (starting at Asp 169) was ligated into 
the pET3d expression vector under the control of the bacter- 
iophage T7 promoter (Fig. 1). When cultured at 37°C, induc- 
tion by 0.4 mM IPTG led to high-level expression of recom- 
binant LO protein (Fig. 2), though essentially all in the form 
of insoluble inclusion bodies. Extracting the pellet with 0.5% 
(v/v) Triton X-100 solubilised small amounts of recombinant 
LO, though efficient extraction required the use of 8 M urea. 
When the urea extract of the Triton-washed inclusion bodies 
was dialysed against PBS, recombinant LO precipitated selec- 
tively out of solution, and could be recovered in essentially 
pure form in the pellet (Fig. 2). 
The selective precipitation of recombinant protein from 
urea extracts of inclusion bodies proved to be a convenient 
method for the preparation of LO antigen for production of 
polyclonal antiserum in rabbits. As shown by Western blot- 
ting (Fig. 3), antibodies raised against he recombinant human 
protein specifically recognised tissue-derived porcine LO, 
where both proteins co-migrated with an apparent molecular 
mass of 32 kDa. LO was also the sole protein to be recognised 
in Western blots of crude, urea extracts from porcine skin (not 
shown). 
Urea extracts of recombinant LO from inclusion bodies 
were devoid of LO activity (after dilution to lower the urea 
concentration) when assayed on a [4,5-3H]lysine labeled elas- 
tin substrate. To avoid possible irreversible denaturation by 
"1"7 RBS 
GAAGGAG ATATACC ATG 
M DDPYNmPatur e LO 
"1"7 RBS 
--------~m-GAAGGAG TATACC ATG 
p._E..T,.2tO,:J~Q MKYLLPTAAAGLLLLAAQPAMAM DDPYNP 
pelb leader mature LO 
Fig. 1. Schematic representation f the expression cassette contained in the pET3-LOm and pET20-LO constructs, designed for expression of 
human LO in the cytoplasmic and periplasmic space, respectively. The ribosome binding site (RBS) sequence is underlined. 







1 2 3 4 5 6 7 
1 ~ ig. 2. Expression of recombinant LO at 37°C. Analysis by SDS- 
P ~,GE, followed by staining with Coomassie Blue. Lane 1: molecu- 
I: r weight markers. Lane 2: cell lysate before induction (100 lag pro- 
t, in). Lane 3: cell lysate after induction (100 lag protein). Lane 4: 
s tpernatant after high-speed centrifugation of the cell lysate shown 
i~ lane 2 (100 lag protein) showing that the recombinant LO is 
n~ostly present in inclusion bodies. Lane 5: supernatant after Triton 
v ashing of inclusion bodies (30 lag protein). Lane 6: Triton washed 
i clusion bodies (30 lag protein). Lane 7: recombinant LO purified 
tom inclusion bodies by urea extraction and subsequent removal of 
t tea by dialysis (20 lag protein). 
t rea extraction, attempts were made to increase the yield of 
s ?luble, recombinant enzyme. It was found that lowering the 
i lcubation temperature during bacterial culture from 37°C to 
22°C led to a marked increase in the amount of soluble LO 
t Fig. 4). A further, small increase in solubility was found after 
1)wering the concentration of IPTG to 0.04 mM. In these 
t onditions, up to 20% of total recombinant LO was recovered 
i l  the soluble fraction, which showed LO activity (Table 1). 
Activity was reduced to control levels (i.e. using extracts from 
cells transformed with non-recombinant vector) when pre-in- 
t ubated (for 2 h) and assayed in the presence of 50 gg/ml 
tlAPN. The maximum amount of soluble LO produced in 
~his way was approximately 5 mg/l of culture. 
In order to investigate the production of active, recombi- 
ant LO in a less reducing environment, an additional expres- 
• ion construct was created (pET20-LO; Fig. 1), in which the 
: ,0 cDNA was ligated downstream of the pelb signal peptide 
, oding region, in order to target the enzyme to the E. coli 
periplasmic space. Western blotting showed that the pelb- 
,O fusion protein was successfully expressed, translocated 
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Fig. 3. Recognition of porcine skin LO by antibodies raised against 
recombinant human LO. (a) SDS-PAGE, Coomassie Blue staining. 
Lane 1: molecular weight markers. Lane 2: partially purified por- 
cine skin LO (active eluate from the Cibacron Blue column; 70 gg). 
Lane 3: purified porcine LO (5 lag). Lane 4: recombinant human 
LO (10 gg). (b) Immunoblot, probed with antibodies to human re- 
combinant LO. Lanes 1 3 are duplicate samples to those analysed 
in lanes 2 4 of part (a), respectively. 
densitometry, approximately 1% of total soluble periplasmic 
protein was recombinant LO, and the total yield of periplas- 
mic, recombinant LO was approximately 0.3 mg/l of culture. 
Compared to the soluble intracellular expression systems 
(above), the periplasm extract showed increased specific LO 
activity on elastin (Table 1). Again, enzyme activity was re- 
duced to background levels in the presence of BAPN. 
4. Discussion 
Using the cytoplasmic expression construct (pET-LO) we 
found that essentially all the recombinant LO was present in 
the form of inclusion bodies. However, when cultures were 
grown at 22°C and induced with reduced amounts of IPTG, 
both solubility and activity of recombinant LO increased. A
similar temperature dependance of solubility has been re- 
ported for the P22 tailspike protein [35], diphtheria toxin 
[36], basic fibroblast growth factor [37] and human UDP-glu- 
curonosyltransferase [38]. 
By SDS-PAGE, recombinant human LO co-migrates with 
purified porcine LO with an apparent molecular mass of 32 
kDa, in agreement with the apparent molecular mass of tis- 
sue-derived LO purified from several species [1,27,39]. The 
predicted molecular mass of the mature form of human LO, 
based on cDNA data, is 29 034 Da. By mass spectrometry, the 
molecular mass of the porcine enzyme (29 377 Da) is similar. 
and both human and porcine LO are known to be highly 
homologous [7]. Therefore the anomalous migration of both 
"able 1 
~ctivity of recombinant human LO on a aH[lysine]-labeled lastin substrate 
'lasmid Net cpm/ml/100 lag protein Net cpm/ml/100 gg protein 
(-BAPN) (+BAPN) 
ntracellular expression 
pET3-LOm (construct) 1450+ 143 (7) 727 + 183 (7) 
pET3d (vector alone) 727 + 157 (3) 733 +_ 177 (3) 
i'eriplasmic expression 
pET20-LO (construct) 2210 _+ 170 (7) 613 +_ 223 (7) 
pET20b (vector alone) 547+ 130 (3) 487 + 157 (3) 
kctivity was assayed in the presence and absence of 50 gg/ml BAPN. Errors are + SEM (with number of assays hown in parentheses), Background 
tctivity (i.e. substrate and assay buffer alone) has been subtracted from the data. 
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recombinant and tissue-derived LO by SDS-PAGE is an in- 
trinsic feature of the amino acid sequence of the protein. 
E. coli transformed with vector alone showed low levels of 
activity (Table 1) which were not inhibitable by BAPN. The 
specificity of the ultrafiltration assay for LO [26] is dependent 
on successful inhibition by the specific inhibitor BAPN. Non- 
inhibitable activity may be due to the presence of an endog- 
enous amine oxidase. It is not known if the E. coli strain 
BL21(DE3) used in this work has endogenous amine oxidase 
activity, though E. coli K12 are known to express a copper- 
dependent amine oxidase which is located in the periplasm 
and induced by phenylethylamine [40]. Successful expression 
of active, human LO in the experiments reported here is dem- 
onstrated by the observation of BAPN-inhibitable activity 
only in extracts of cells transformed with the LO encoding 
constructs. 
The specific activity of the isolated, recombinant, periplas- 
mic LO can be estimated from the data shown in Fig. 5 and 
Table 1. Assuming that 100 p.g of crude extract contains 1~tg 
LO, the specific activity of the recombinant enzyme (after 
substraction of endogenous activity) is approximately 1660 
cpm/ml/~tg. This is similar to the specific activity of the tis- 
sue-derived enzyme from porcine skin (1730 cpm/ml/ktg ). 
It is well established that purification of LO from various 
sources requires use of high concentration of urea for the 
extraction of the protein from the extracellular matrix [1]. 
After removal of urea, the enzyme polymerises [14], which 
suggests that this is the native form of the enzyme in physio- 
logical buffers. In the work presented here, we have demon- 
strated that human LO can be expressed in soluble form in E. 
coli. It is possible therefore that the aggregation of tissue- 
derived LO could be a consequence of partial denaturation 
by exposure to high concentrations of urea. 
A number of copper-dependent amine oxidases have now 
been identified or overexpressed in E. coli. These include a 
monoamine oxidase of the E. eoli strain K-12, whose 3-dimen- 
sional structure has recently been determined by X-ray crys- 
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Fig. 4. Intracellular expression of recombinant human LO. Analysis 
by SDS-PAGE, followed by staining with Coomassie Blue. Lanes 
1-3: supernatants after high-speed centrifugation f cell lysates (100 
ktg protein), after culture at (1) 37°C, induction with 0.4 mM IPTG 
(2) 22°C, induction with 0.4 mM IPTG (3) 22°C, induction with 
0.04 mM IPTG. Lane d: molecular weight markers. 
M. Ouzzine et al.IFEBS Letters 399 (1996) 215-219 
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Fig. 5. Expression of recombinant, human LO in the bacterial peri- 
plasm. (a) SDS-PAGE, Coomassie Blue staining. Lane 1: recombi- 
nant LO purified from inclusion bodies produced in cells harbouring 
pET3-LOm (20 /.tg protein). Lane 2: periplasmic fraction of cells 
transformed with pET20-LOm, cultured at 22°C after induction 
with 0.04 mM IPTG (100 lag protein). Lane 3: periplasmic fraction 
before induction (100 lag protein). (b) Immunoblot. Lane 1: recom- 
binant LO from inclusion bodies (20 lag protein). Lane 2: periplas- 
mic fraction after induction (100 lag protein). Lane 3: perisplasmic 
fraction before induction (100 ~tg protein). Recombinant LO under- 
goes limited degradation during storage (lane 1). 
histamine oxidase [12] from Arthrobacter globiformis. Overex- 
pression of the A. globiformis enzymes in the absence of cop- 
per, and subsequent activation by added copper, has demon- 
strated that, at least in vitro, production of the topaquinone 
co-factor is not dependent on an additional enzymatic step 
[43]. In LO, the organic co-factor has recently been shown 
to be lysine tyrosylquinone (LTQ) [14]. The successful expres- 
sion of active human LO in E. coli reported here shows that 
formation of LTQ is not a limitation of using a bacterial 
expression system, and suggests that this modification may 
also occur in the absence of an additional enzyme. Production 
of milligram amounts of recombinant, human LO now paves 
the way for detailed, 3-dimensional structural analysis of this 
enzyme. 
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